This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Although the deadline for achieving the commitment has been postponed by the Government until 2026, the evidence available to us indicate that it is not likely to be met by this deadline either.‘ The report stated: ‘This commitment will not be achieved by 2024, with only 3% of Trusts having achieved the commitment so far.
The much-anticipated and long-overdue plan details a programme of ambitious incremental growth for pharmacist education and training , which will see an initial rise in training places of 15% in 2026/27, followed by a 29% increase to around 4,300 by 2028/29, before reaching the +50% target by 2031/32.
Ahead of the UK’s 2026 regulatory changes, which will give all new pharmacist registrants full and independent prescribing rights, a new paper offers a critique of a Pharmacist Clinician Model, outlining the need for such a model and offering a systematic approach to its safe and effective development. Reference Rushworth, G et al.
As hospital pharmacists continue to expand their roles, the ability to prescribe medications either independently or in collaboration with medical prescribers presents an opportunity to alleviate the growing pressure on healthcare systems while enhancing patientcare. of all UK registered pharmacists.
Each focuses on providing health care quality experience to diverse individuals from diverse disciplines. PQA is now accepting applications for our student and professional programs for 2025-2026. She addressed working with health plans on new programs and services that create patient impact.
Name: Tonisha Gaitor School: University of Georgia Major/Degree Program: PharmD/MBA Anticipated Year of Graduation: 2026 What drew you to PQA and our work to improve medication use safety, adherence, and appropriate use? What do you hope to learn this summer at PQA to take back with you to school this fall?
For John Warburton, divisional director of professions at University Hospitals Bristol and Weston NHS Foundation Trust and chair of the UK Clinical Pharmacy Association (UKCPA) , one of the most transformative changes in clinical pharmacy is the introduction of independent prescribing for newly qualified pharmacists from 2026.
On June 12, 2024, the FDA released a notice stating that it is issuing exemptions from specific requirements of the DSCSA to small pharmacies to go into effect on 11/27/2024 to ensure patient access. The exemption will last until November 27, 2026, for those small dispensers who qualify. The DiversifyRx team is always here to help.
Payers are eager to engage pharmacies in driving better patientcare and outcomes, but for this effort to be successful, consistent and reliable methods are needed to measure pharmacists contributions to care. Results from this two-year project will be shared in 2026.
By 2026, the site will produce 80% of its electricity consumed on-site and aims to be a net-zero greenhouse gas emissions site by 2030. Takeda has reduced CO2 emission by 861 tons. Over the past five years the entire Lessines production site has reduced its operational carbon footprint by 45% or the equivalent of 5,500 tons of CO2.
‘But increasingly, we have changes in policy and agendas that are almost begging us to be involved in hands-on clinical care.’ From 2026 all UK pharmacy graduates will be eligible to prescribe after successful completion of their days in practice and year of foundation training.
COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Telemedicine rose dramatically in many countries, providing a route to managing ongoing care which was a lifeline for many patients.
Members of the Royal Pharmaceutical Society (RPS) have voted in favour of proposed changes that will see it become a Royal College by Spring 2026. Our ambition is to create greater recognition for pharmacy with the public, policy makers and other healthcare professionals and drive excellence in patientcare.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content